Is the GLP-1 receptor agonist, semaglutide, a good option for weight loss in persons with HIV?-Reference-Cited by-同舟云学术

Is the GLP-1 receptor agonist, semaglutide, a good option for weight loss in persons with HIV?

Published:2024-02-29 Issue:4 Volume:38 Page:603-605
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Lee Daniel¹,Capeau Jacqueline²

Affiliation:

1. University of California, San Diego Health, Owen Clinic, Division of Infectious Diseases & Global Public Health, San Diego, California, USA

2. Inserm UMR_S938, Centre de Recherche Saint-Antoine, Institut Hospitalo-Universitaire de Cardio-Métabolisme et Nutrition (ICAN), Sorbonne Université, Paris, France.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference21 articles.

1. Editorial commentary: weight loss for cardiovascular disease prevention − is semaglutide the answer?;Lavie;Trends Cardiovasc Med,2023

2. Changes in weight and weight distribution across the lifespan among HIV-infected and -uninfected men and women;Erlandson;Medicine (Baltimore),2016

3. Obesity and weight gain in persons with HIV;Bailin;Curr HIV/AIDS Rep,2020

4. HIV and antiretroviral therapy-related fat alterations;Koethe;Nat Rev Dis Primers,2020

5. Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV;Capeau;Curr Opin HIV AIDS,2024

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Semaglutide in people with HIV-associated lipohypertrophy;The Lancet Diabetes & Endocrinology;2024-08

2. HIV and adipose tissue: A long history linked to therapeutic classes of antiretrovirals;Annales d'Endocrinologie;2024-06